Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.46 |
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295881 | 0.93 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL2200199 | 0.93 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL28295882 | 0.93 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL30525295 | 0.90 | DPP4 (0.55) | NOD1DPP8DPP9DPP4 | |
| SCHEMBL30591036 | 0.88 | DPP4 (0.52) | NOD1DPP8DPP9DPP4 | |
| SCHEMBL31433224 | 0.88 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL34464998 | 0.86 | DPP4 (0.51) | NOD1DPP8DPP9DPP4 | |
| SCHEMBL30799479 | 0.86 | BACE1 (0.47) | NOD1 | |
| SCHEMBL31433194 | 0.86 | NOD1 (0.47) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29978904 | 0.84 | DPP4 (0.49) | NOD1DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NOD1 1477/4885DPP8 1446/4885DPP9 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.